Abstract
Background: Cancer is a major cause of death worldwide, despite many different drugs available to treat the disease. This high mortality rate is largely due to the complexity of the disease, which results from several genetic and epigenetic changes. Therefore, researchers are constantly searching for novel drugs that can target different and multiple aspects of cancer.
Experimental: After a screening, we selected one novel molecule, out of ninety-four triazole derivatives, that strongly affects the viability and proliferation of the human breast cancer cell line MCF-7, with minimal effects on non-cancer cells. The drug, named DAN94, induced a dose-dependent decrease in MCF-7 cells viability, with an IC50 of 3.2 ± 0.2 µM. Additionally, DAN94 interfered with mitochondria metabolism promoting reactive oxygen species production, triggering apoptosis and arresting the cancer cells on G1/G0 phase of cell cycle, inhibiting cell proliferation. These effects are not observed when the drug was tested in the non-cancer cell line MCF10A. Using a mouse model with xenograft tumor implants, the drug preventing tumor growth presented no toxicity for the animal and without altering biochemical markers of hepatic function.
Results and Conclusion: The novel drug DAN94 is selective for cancer cells, targeting the mitochondrial metabolism, which culminates in the cancer cell death. In the end, DAN94 has been shown to be a promising drug for controlling breast cancer with minimal undesirable effects.
Keywords: Reactive oxygen species, Cell cycle, Viability, Cancer, Apoptosis, Novel triazole.
Current Topics in Medicinal Chemistry
Title:A Novel Triazole Derivative Drug Presenting In Vitro and In Vivo Anticancer Properties
Volume: 18 Issue: 17
Author(s): Ricardo Imbroisi Filho, Daniel T.G. Gonzaga, Thainá M. Demaria, João G.B. Leandro, Dora C.S. Costa, Vitor F. Ferreira, Mauro Sola-Penna, Fernando de C. da Silva*Patricia Zancan*
Affiliation:
- Instituto de Quimica, Campus do Valonguinho, Universidade Federal Fluminense, Niteroi-RJ, 24020-141,Brazil
- Laboratorio de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmaceutica, Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902,Brazil
Keywords: Reactive oxygen species, Cell cycle, Viability, Cancer, Apoptosis, Novel triazole.
Abstract: Background: Cancer is a major cause of death worldwide, despite many different drugs available to treat the disease. This high mortality rate is largely due to the complexity of the disease, which results from several genetic and epigenetic changes. Therefore, researchers are constantly searching for novel drugs that can target different and multiple aspects of cancer.
Experimental: After a screening, we selected one novel molecule, out of ninety-four triazole derivatives, that strongly affects the viability and proliferation of the human breast cancer cell line MCF-7, with minimal effects on non-cancer cells. The drug, named DAN94, induced a dose-dependent decrease in MCF-7 cells viability, with an IC50 of 3.2 ± 0.2 µM. Additionally, DAN94 interfered with mitochondria metabolism promoting reactive oxygen species production, triggering apoptosis and arresting the cancer cells on G1/G0 phase of cell cycle, inhibiting cell proliferation. These effects are not observed when the drug was tested in the non-cancer cell line MCF10A. Using a mouse model with xenograft tumor implants, the drug preventing tumor growth presented no toxicity for the animal and without altering biochemical markers of hepatic function.
Results and Conclusion: The novel drug DAN94 is selective for cancer cells, targeting the mitochondrial metabolism, which culminates in the cancer cell death. In the end, DAN94 has been shown to be a promising drug for controlling breast cancer with minimal undesirable effects.
Export Options
About this article
Cite this article as:
Filho Imbroisi Ricardo , Gonzaga T.G. Daniel , Demaria M. Thainá, Leandro G.B. João , Costa C.S. Dora , Ferreira F. Vitor , Sola-Penna Mauro , de C. da Silva Fernando *, Zancan Patricia *, A Novel Triazole Derivative Drug Presenting In Vitro and In Vivo Anticancer Properties, Current Topics in Medicinal Chemistry 2018; 18 (17) . https://dx.doi.org/10.2174/1568026618666180917100640
DOI https://dx.doi.org/10.2174/1568026618666180917100640 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Intestinal Microbiota in Graft versus Host Disease
Mini-Reviews in Medicinal Chemistry The Importance and Evolution of Radiation Dose in DCIS
Current Cancer Therapy Reviews Metallothionein as a Negative Regulator of Pulmonary Inflammation
Current Pharmaceutical Biotechnology Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry Drug Metabolism and Individualized Medicine
Current Drug Metabolism Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
Clinical Cancer Drugs Cubosomes: Versatile Nanosized Formulation for Efficient Delivery of Therapeutics
Current Drug Delivery Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Molecular Mapping and Docking Interactions for Selective Anti-Fertility Potency of Estrogen Analogs
Letters in Drug Design & Discovery A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer
Current Pharmaceutical Design